COMPANY PROFILE

lepidyne

Explore full profile

Lepidain, a global cancer diagnostic company, is developing an out-of-body diagnostic device based on methylization

Seoul, South KoreaFounded 2019Wellness Beauty

Valuation $50–100M Last recorded · 2023

Total funding $10–50M Disclosed equity funding

Unlock exact values

About lepidyne

Lepidyne is a pioneering company in the field of cancer diagnostics, focusing on the development of advanced diagnostic devices and kits for early detection and monitoring of liver cancer. The company serves healthcare providers, research institutions, and clinical laboratories, operating within the global medical diagnostics market. Lepidyne's business model revolves around the creation and sale of diagnostic kits and devices, which generate revenue through direct sales and long-term contracts with medical institutions. The company's flagship products include an early diagnosis kit for liver cancer, a monitoring kit for tracking liver cancer treatment progress, and a forecasting kit for liver tissue health. Lepidyne leverages cutting-edge technology such as blood biopsies and methylation markers to provide accurate and reliable diagnostic results. The company aims to improve patient outcomes by enabling early detection and effective monitoring of liver cancer, ultimately contributing to better treatment strategies and increased survival rates.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Seoul, South Korea
Open positions: None listed
Dealroom signal: 19.0/100
Industry: Wellness Beauty
Sector: Wellness Beauty, Hard Tech
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Apr 2023	$8.6M	$34M	Undisclosed	—
SERIES A✓Equity / VC	Dec 2019	$3.8M	$15M	IBK Capital · DSC Investment · Seoul Investment Partners	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

lepidyne website traffic

Latest recorded traffic for lepidyne is 160 monthly website visits, down 27.3% over the last three months.

Latest monthly visits160 3-month web change-27.3%

Monthly website visitsJun 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EMEmmA custom fit smart menstrual cup that helps to understand body better	Bristol, United Kingdom	Operational	50	$11M	$36M
LHLene HealthFast and legally secure assessment of the psychological risk assessment guiding employees to their healthier self	Hanover, Germany	Operational
LILissunProvides end-to-end solutions for better Mental Wellness	Gurugram, India	Operational
MEMeWe&YouHelping women have a healthier and happier menopause - every day	Luleå kommun, Sweden	Operational
OROrwellMakes mental health services more convenient and more interesting	Seoul, South Korea	Operational
ELElevateMeAt-home blood tests with personalized AI-driven health insights	London, United Kingdom	Operational
BOBioMinds Healthcare Sp. z o.o.A new way for neurological rehabilitation - system for remote rehabilitation operating in augmented and virtual reality for sick and healthy persons	Lublin, Poland	Operational
DIDinaFocused on helping people get well faster and stay well longer in the comfort of their home	Chicago, United States	Acquired